Kazia Therapeutics Limited
KZA.AX
Australian Securities Exchange0.08
AUD
+0.01
- -
Kazia Therapeutics Limited
KZA.AX
(Australian Securities Exchange)
Recent
price
0.08
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), a clinical-stage oncology-focused biotechnology company founded in 1994 and headquartered in Sydney, Australia, develops innovative small-molecule drugs targeting high-need cancers, particularly of the central nervous system and solid tumors. The company's lead product candidate, paxalisib (formerly GDC-0084, licensed from Genentech), comprises a brain-penetrant dual inhibitor of the PI3K/mTOR pathway in clinical development for glioblastoma multiforme (including newly diagnosed and recurrent forms), diffuse intrinsic pontine glioma, triple-negative breast cancer, and other solid tumors; EVT801 (licensed from Evotec SE in April 2021), a selective VEGFR3 inhibitor for advanced solid tumors demonstrating preclinical synergy with immuno-oncology agents and completing Phase I with data presented in September 2024; and additional pipeline assets including a PD-L1 degrader program and early-stage candidates such as triphendiol and anisina. Kazia operates globally with clinical trials conducted in the United States, Europe, and Australia, serving patient populations with limited treatment options through partnerships with leading institutions and leveraging orphan drug designations for accelerated pathways. In recent developments, Kazia completed a $50 million private placement of equity securities in December 2025 with institutional investors including Adar1 Capital Management and Ikarian Capital to fund paxalisib advancement into brain cancer and breast cancer trials, PD-L1 degrader progression, and operations through mid-2028; reported an immune complete response in metastatic triple-negative breast cancer with paxalisib combined with Keytruda and chemotherapy; initiated new paxalisib trials and completed last patient follow-up in EVT801 Phase I; and requested FDA Type C meeting under Project Frontrunner for glioblastoma approval pathways, following a January 2025 $2 million registered direct offering.